KRAS and colorectal carcinoma: To date, however, none of these markers has been introduced into routine clinical practice for the treatment of CRC, with the exception of recent and consistent evidence for Kras mutation being predictive for non-response to anti-EGFR treatment (Amado et al, 2008; Bokemeyer et al, 2008; Karapetis et al, 2008; de Roock et al, 2008; van Cutsem et al, 2008).